Story perspectives

Genscript Shares Jump as AI Lifts Profit 203%

8/17/2026

Summary

Story summary

WuXi AppTec’s shares rose 3 percent to HK$203.40, showing resilience despite Washington’s push to curb Chinese reliance.
Genscript Biotech’s shares climbed 4.8 percent to HK$26.08.
Genscript reported an adjusted net profit of US$62.52 million—a 203 percent rise for the six months ended June 30—and lifted its life-science service growth outlook to 25-30 percent, citing AI-driven gene-to-protein demand.
Chief Financial Officer Phil Zhou said AI-driven drug-discovery orders will double in the second half and remain strong.

1 of 1

Story summary

WuXi AppTec’s shares rose 3 percent to HK$203.40, showing resilience despite Washington’s push to curb Chinese reliance.
Genscript Biotech’s shares climbed 4.8 percent to HK$26.08.
Genscript reported an adjusted net profit of US$62.52 million—a 203 percent rise for the six months ended June 30—and lifted its life-science service growth outlook to 25-30 percent, citing AI-driven gene-to-protein demand.
Chief Financial Officer Phil Zhou said AI-driven drug-discovery orders will double in the second half and remain strong.